Cannabidiol (CBD) is a compound found in cannabis plants that has been gaining popularity due to its potential therapeutic and medicinal qualities. With the exception of Epidiolex, CBD oil and other products containing CBD are not approved or regulated by the FDA. Under federal law, CBD derived from cannabis plants with more than 0.3% THC is considered a Schedule I controlled substance. However, the Drug Enforcement Administration (DEA) has recently removed Epidiolex from the list of federally controlled substances, making it a Schedule V controlled substance.
This means that all individuals in the supply chain who handle Epidiolex in the United States must comply with the requirements of the CSA and DEA regulations related to Schedule V controlled substances. Any material, compound, mixture or preparation other than Epidiolex that falls within the CSA definition of marijuana set forth in 21 U. S. C.
§ 802(16) will remain a Schedule I controlled substance. Therefore, people who handle such items will continue to be subject to the requirements of the CSA and DEA regulations related to Schedule I controlled substances. The legal status of CBD is still somewhat confusing, as it depends on the type of plant from which it is derived and the amount of THC present in both the original plant and the final product. CBD derived from hemp plants with less than 0.3% THC is not considered a controlled substance and is legal at the federal level.
However, CBD products containing THC could cause someone to fail a screening test, so it is important to be aware of this when purchasing CBD products. In conclusion, while Epidiolex has been removed from the list of federally controlled substances, other forms of CBD remain a Schedule I controlled substance and are subject to the requirements of the CSA and DEA regulations related to Schedule I controlled substances.
